• Objectives: To assess the incremental burden of Clostridium difficile-associated diarrhea (CDAD) in subpopulations at elevated risk of CDAD recurrence: immunocompromised, CDAD history, concomitant antibiotic use (cABx), renal impairment, inflammatory bowel disease (IBD), and elderly.
T he widespread use of broad-spectrum antibiotics [1, 2] and the emergence of a hypervirulent strain of Clostridium difficile, a gram-positive, sporeforming anaerobic bacillus [3] [4] [5] , have been linked to the increasing incidence and severity of C. difficile-associated diarrhea (CDAD) [6] [7] [8] . Kuntz et al reported an incidence of 284,875 C. difficile infections during 2007 in the United States [9] . In 2009, a total of 336,600 hospital stays in the US were linked to CDAD, with about a third listing CDAD as the primary diagnosis [10] . Extrapolating data from Massachusetts hospitals, O'Brien et al conservatively estimated the annual costs associated with the management of CDAD in the United States at $3.2 billion. An economic simulation model developed by McGlone et al found the median cost of a CDAD case ranged from $9179-$11,456 for hospitals and $8932-$11,679 and $13,310-$16,464 from the payer and societal perspectives, respectively. In a conservative estimate [12] , Dubberke et al showed that CDAD accounted for a $2500-$3500 increase in costs for the index hospitalization [13] . The McGlone et al model demonstrated the annual economic burden for CDAD in the United States was approximately $496 million, $547 million, and $796 million from the hospital, payer, and societal perspectives, respectively [14] . Inpatient hospitalization is a major cost category, as CDAD increases hospital length of stay (LOS) and costs among infected patients [15, 16] . These studies help elucidate the economic picture of CDAD for different stakeholders and for society [14, 17, 19] . The burden of CDAD, as measured by extended hospital stays and increased inpatient and post-discharge costs, may be related to increased cost of care (eg, CDAD-specific staff time and diagnostic and surgical procedures), relapses, rehospitalizations, and the use of antibiotics as CDAD treatment [11] .
While the increasing burden of CDAD has been evaluated in general and within several specific population segments at risk for CDAD [11, 17, [19] [20] [21] [22] [23] , some subgroups, especially elderly patients [24] , antibiotic users [25, 26] , immunocompromised patients [27, 28] , and those requiring prolonged periods of hospitalization for conditions such as renal impairment [29] [30] [31] and inflammatory bowel disease (IBD) [19, [32] [33] [34] [35] are at higher risk for recurrent CDAD, C. difficile co-infections, and increased morbidity and mortality [20] [21] [22] [23] 36 ]. Yet, limited information is currently available that determines the additional burden associated with these higher at-risk groups. Therefore, the objective of this study was to determine the incremental differences in length of index hospital stay and cost, and to evaluate the post-discharge burden (health care-related event and pharmacy costs) among selected groups of patients at risk for CDAD vs. those not at increased risk.
METHODS

Data Source and Study Design
This retrospective cohort study utilized the integrated eligibility, medical, and pharmacy data contained in the HealthCore Integrated Research Database (HealthCore Inc., Wilmington, DE) to identify patients diagnosed with CDAD between 01/01/2005 and 10/31/2010. The database contains administrative claims data for approximately 38.5 million Americans covered by 14 commercial health care plans in the northeastern, southeastern, mid-Atlantic, midwestern, and western regions of the United States from 01/01/2004. This study complied with the Health Insurance Portability and Accountability Act (HIPAA) of 1996, and patient confidentiality and anonymity were preserved via de-identification.
Patient Sample
Among CDAD cases, the index date was defined as the earliest medical claim for a CDAD diagnosis code (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM]; 008.45) within an inpatient setting during the patient identification period. Index hospitalization was defined as the inpatient encounter from which the index date was identified. To be included, patients were required to be ≥ 18 years of age on the index date with ≥ 12 months of continuous and concurrent medical and pharmacy enrollment preceding the index date (ie, the baseline period).
Definition of High-Risk Subgroups
Immunocompromised
Immunocompromised patients included transplant recipients (index hospitalization), those receiving chemotherapy or immunosuppressant treatments (during or in the preceding 30 days of the index hospitalization) and those diagnosed with HIV and/or AIDS (baseline and index hospitalization).
CDAD History
CDAD history patients were those with a pre-index diagnosis of CDAD during the 12-month baseline period.
Concomitant Antibiotic Use
Concomitant antibiotic users (cABx) were those receiving antibiotics during the index hospitalization or period leading up to the index hospitalization where antibiotic supply overlapped with the index hospitalization.
Renal Impairment
Patients with renal impairment encompassed those with ICD-9-CM diagnosis/procedure codes for nephrosis, glomerulonephritis, nephropathy, impaired renal function/manifestations, renal failure, renal sclerosis, or acute and/or chronic kidney disease (CKD) during the index hospitalization.
IBD
IBD patients included those with an ICD-9-CM diagnosis code for ulcerative colitis (555.xx) or Crohn's disease (556.xx) any time during the index hospitalization.
Elderly
Elderly patients were those aged ≥ 65 years as of the index hospitalization.
Attribute Matching and Control Sample
Controls were derived from the HealthCore database and were required to be ≥ 18 years of age, have ≥ 12 months of continuous medical and pharmacy eligibility prior to the index inpatient encounter, and have ≥ 1 medical claim for at least 1 of the above high-risk conditions.
Once each of these high-risk subgroups was defined among the overall pool of cases and controls, each sub-www.jcomjournal.com C. diffiCile-associated diarrhea population for the cases was matched independently to the corresponding pool of control patients without an inpatient CDAD diagnosis. Initially, cases and controls were matched on the subgroup defining condition prior to fulfilling any other matching criteria. If a subgroup condition was defined by the presence of multiple conditions, then each case was matched to a control with the exact profile of the corresponding subgroup defining condition ( Table 1) . For example, within the immunocompromised subgroup, a case was matched to a corresponding control based on the mirrored presence of each condition used for defining immunocompromised: chemotherapy, immunosuppressants, transplantation, stem cell/bone marrow transplantation, and HIV/AIDS.
Subsequently, a secondary match was applied between corresponding cases and controls on additional conditions to control for other factors potentially driving resource utilization and costs. To control for variations in comorbidities, the top 100 baseline and index hospitalization conditions among CDAD patients were identified and categorized into 6 major classes-diabetes mellitus, cardiovascular, pulmonary, musculoskeletal, hematopoietic, and antibiotic-associated conditions. The secondary matching criteria thus included the remaining subgroups, age (± 10 years) as of the hospitalization, gender, and baseline and/or in-hospital presence of each major comorbid class.
Where multiple encounters of a matched control were available for any given case, the earliest occurring encounter was selected. Matching continued until a 1:3 casecontrol ratio was obtained for each subgroup member where feasible (ie, where sufficient control sample was available). For example, for the CDAD history and IBD groups, age ± 10 years and musculoskeletal conditions were excluded as matching criterion to prevent match rates from dropping below 70%, and only 1 and 2 controls per case could be obtained, respectively. Controls were selected independently for each at-risk group. That is, a patient identified as a suitable control in 1 risk group could still be considered as a potential control for other risk groups.
The intent behind the hierarchical attribute matching approach was to account for the secondary nature of CDAD. Since the underlying conditions themselves could be considered major drivers of resource use and cost burden to managed care, we focused on the 6 primary patient groups that we believed to be associated with the greatest risk of acquiring CDAD. The assumption was that these subpopulations are expected to present the largest resource and highest cost burden to managed care. Furthermore, this approach of performing a direct match on cases and controls with the same underlying primary at-risk condition was employed to help mitigate potential confounding, thus reducing the variance of our outcomes (ie, CDAD-related costs and utilization) within each of the subgroups.
Definition of Follow-Up
Follow-up was the period between the discharge date of the index hospitalization and the earliest of (a) end of continuous health plan eligibility, (b) end of available data stream (10/31/2010), or (c) death. To adjust for variations in follow-up period between patients, permember per-month (PMPM) costs were calculated as all costs accrued by the patient for posthospitalization visits and treatments occurring after the hospital discharge date divided by the number of eligibility months; costs accrued from the date of admission to the discharge date were assessed as index hospitalization costs. Incremental PMPM costs were further stratified into medical and pharmacy components (ie, costs calculated on the basis of pharmacy claims) and were defined as the difference in monthly costs paid by the health plan over the entire duration of follow-up between cases and controls. Due to the secondary nature of CDAD, costs were all-cause and not limited to CDAD-related pharmacy claims.
Statistical Analyses
Descriptive Statistics
Prior to matching, continuous characteristics were represented using means and standard deviations, while categorical variables were evaluated as percentages. T-tests for continuous variables and  2 tests for categorical variables were used to determine significant differences between cases and controls (P < 0.05). Post-match imbalances were assessed by evaluating the standardized differences between cases and controls with imbalance defined as an absolute value greater than 10%.
Multivariate Analysis
Baseline characteristics of the case and control groups indicated no significant differences (absolute standardized difference ≤ 10%) with regard to the targeted match criteria. To further account for potential confounding effects that may have persisted after matching, multivariate generalized linear regression models were developed to evaluate the significance and estimate the adjusted magnitude of the incremental hospital LOS and costs (in-hospital and follow-up PMPM costs) between cases and controls. The generalized linear regression models employed a logarithmic link function with gamma distribution. Covariates included characteristics that remained significant postmatch between the cases and controls. 
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Age ± 10 years √ √ √ √ cABx = concomitant antibiotic users; CDAD = Clostridium difficile-associated diarrhea; DCI = Deyo-Charlson Comorbidity Index; IBD = inflammatory bowel disease.
*High-risk defining subgroup. † Comorbid class of baseline and in-hospital conditions. ‡ Diabetes mellitus type 1 or 2 (index hospitalization). § Cardiovascular conditions include myocardial infarction, heart failure, peripheral vascular disease, stroke, acute coronary syndrome, transient ischemic attack, cardiomyopathy, conduction disorders, lipid metabolism disorders, cardiovascular symptoms and complications, endocardium (index hospitalization); dysrthymias, angina (baseline and index hospitalization).
||
Pulmonary conditions include emphysema, chronic airway obstruction, bronchitis, asthma, pneumonitis, hypostatis and/or lung disease (index hospitalization). ¶ Hematopoietic conditions include iron deficient anemia, aplastic anemia, other anemias, purpura, diseases of the white blood cells and/or coagulation disorders (index hospitalization). **Antibiotic administration-requiring conditions include pneumonia, pleurisy, infections, symptoms involving skin and other integumentary tissue and acute upper respiratory infections of multiple or unspecified sites (index hospitalization). † † Musculoskeletal conditions include osteoarthrosis, joint disorders, spondylosis, disc and back disorders, fascia, enthesopathies, rhuematism of tissues and cartilage (baseline and index hospitalization).
www.jcomjournal.com
C. diffiCile-associated diarrhea RESULTS
Patient Disposition
A query of 38.51 million health plan members in the database identified 24,338 patients with ≥ 1 inpatient medical claim for CDAD during the study period. A total of 21,177 patients met the age and eligibility requirements and were included in the study. From these, 6 high-risk subgroups were identified: immunocompromised: n = 4916; CDAD history: n = 1185; cABx: n = 4887; renal impairment: n = 6100; IBD: n = 1782; and elderly: n = 12,476 ( Table 2) . Descriptions of select characteristics of the case and control groups, post-match, are summarized below.
Post-Match Demographic and Clinical Characteristics at Baseline and Index Hospitalization
Immunocompromised This patient cohort consisted of 3586 cases and 10,758 controls, with ~53% female, and a mean age of ~64.5 years ( Table 3 ). 
Elderly
The case group contained 10,993 patients, while the control group included 32,799 patients. Females accounted for 62.3% of the patient population. The mean (± SD) age was 80 (± 7.9) years for cases and controls. All patients had at least 1 condition that required antibiotic intervention, and primary comorbidities included cardiovascular (85.5%), pulmonary (54.6%), and musculoskeletal (90.6%) diseases. Cases had significantly lower mean DCI scores compared with controls (3.7 [± 2.9] vs. 4.4 [± 3.4], respectively).
Incremental Index Hospitalization Burden
LOS
Multivariate analysis of the incremental LOS for CDAD patients indicated that for all 6 at-risk subgroups, LOS was significantly longer for patients in the case group vs. controls ( Table 4) . CDAD cases had significantly greater inpatient LOS (P < 0.001). www.jcomjournal.com C. diffiCile-associated diarrhea 35 Table 5 ).
In-hospital Costs
DISCUSSION
This study was designed to test for incremental differences in LOS and costs of hospitalized patients whose underlying comorbidities elevated their risk for recurrence of CDAD. While CDAD has previously been associated with increased hospital length of stay and greater costs, such outcomes were found to be even higher among patients DCI score, mean ± SD* 6.0 ± 3.6 6.5 ± 3.7 3.7 ± 2.8 4.8 ± 3.3 3.2 ± 3.1 3.8 ± 3.6 4.6 ± 3.0 5.1 ± 3.4 1.7 ± 2.4 2 ± 2.7 3.7 ± 2.9 4.4 ± 3.4
All-cause mortality, %   37  39  31  30  21  20  36  35  13  10  38  35 During index hospitalization considered at high risk for CDAD and its recurrence. In all 6 at-risk categories, CDAD cases had a significantly greater LOS in addition to inpatient and post-discharge costs, than matched controls without CDAD The added economic burden associated with CDAD found in this study is consistent with the overall LOS and cost trends reported in prior observational studies among CDAD patients [11, 13, [15] [16] [17] [18] [19] . Forster et al showed a 6-day increase in hospital LOS was attributable to C. difficile infections in a hospitalized cohort [15] . In a multihospital study cohort, Pakyz et al showed the adjusted mean costs associated with CDAD cases ($55,769) were significantly higher than for controls ($28,609), and the adjusted mean LOS was 21 vs. 10 days, respectively [16] . One study by Anantakrishnan et al reported CDAD patients with comorbid IBD had a 3-day longer LOS compared with patients diagnosed with only CDAD or IBD [11] . This result was consistent with our finding: IBD patients with CDAD had an incremental 3.3 days of longer hospital stay relative to controls. Furthermore, in the Anantakrishnan et al study, CDAD patients incurred incremental hospitalization costs of $11,346 vs. CDAD patients without underlying IBD; this was similar to the $11,179 difference in cost found www.jcomjournal.com
Original research
C. diffiCile-associated diarrhea
in IBD patients with CDAD in the current study. One major difference between this and the Anantakrishnan et al study [11] is that the latter examined IBD vs. non-IBD patients as a subset of CDAD cases. The current study, in contrast, was designed to determine incremental burden associated with CDAD within a primary at-risk population, controlling for potential confounders that could misrepresent the magnitude of the incremental differences in LOS and costs attributable to CDAD. A matching algorithm was employed specific to each high-risk sub-group in addition to multivariate methods adjusting for factors not adequately controlled for by the matching criteria. Both methods were used to balance underlying confounders, which would likely obscure any differences in index hospital and PMPM cost estimates between cases and controls. In this study, the selection of at-risk groups provided a contextual view of the incremental economic burden associated within a CDAD patient population since CDAD often occurs as a secondary condition in the midst of multiple comorbidities and/or advanced age. Nonetheless, these findings concur with the majority of prior studies that linked CDAD with higher health care-associated economic burdens [11, 13, [17] [18] [19] 37] . The current study results, regardless of their methodological variations, are instructive to health planners and decision makers responsible for allocating limited health care resources [14] . These results represent actionable data that may help with decisions related to the management of CDAD cases with specific underlying conditions, who are at greater risk of recurrent CDAD. By identifying high-risk underlying comorbidities among CDAD cases, the findings of this study also have important implications for payers to proactively manage such patients to avoid re-hospitalizations and other additional high-cost health care use.
A limitation of this claims dataset was that use of orally administered medications for treating CDAD and other comorbid conditions in the hospital setting were bundled into assigned diagnosis-related groups and could not be individually identified. Only medications coded using the Healthcare Common Procedure Coding System could be identified individually; these include only IV and parenteral medications, categories not commonly used in CDAD treatment. Subsequently, while treatment modalities were not differentiated in this study, further exploration of the PMPM burden estimates to assess any differential impact of available antibiotic treatments on clinical and economic outcomes would be worthwhile [2, [38] [39] [40] .
This study used a rich repository of inpatient and outpatient medical and pharmacy data to identify CDAD patients and to construct clinical and CDAD-associated economic profiles for patients. Nonetheless, the data were subject to the limitations typically associated with using data collected from patient claims transactions for research purposes [20] . Another drawback was that *Post-index discharge incremental burden paid by the health plan on a per-month basis for the period of enrollment and is adjusted to 2011 dollars; it was derived from a GLM with gamma distribution and was controlled for multiple factors with significant difference between the cases and controls.
the study included patients with a diagnosis of CDAD in any diagnosis field during the course of their hospitalization. Thus, no differentiation was made between patients who were admitted with CDAD and those who acquired CDAD while hospitalized. Secondly, since this study focused on specific subpopulations rather than on all patients with CDAD, the results cannot be generalized to an overall managed care CDAD population. Additionally, there was a low match rate for the subgroup of patients with a history of previous CDAD, which is one of the strongest risk factors for future CDAD. Lastly, the DCI scores were also marginally higher among patients in the control cohorts as compared to the case cohorts. While the DCI scores were controlled for in the multivariate analysis to reduce any potential bias introduced into the results, it is also likely that these adjusted values underestimate rather than overestimate any actual underlying differences.
One of the unique elements of this study was that the sample, drawn from a large managed care database, provided a large and varied pool of controls, long followup durations, and ultimately resulted in precise point estimates as demonstrated by the narrow confidence intervals. However, this population, comprising mostly working-age adults, is also more likely to be healthier than the general population. These factors make it challenging to generalize or replicate the study findings across other demographics.
The significantly greater LOS, hospitalization, and post-discharge costs demonstrated in this study reflect the significant incremental economic burden for CDAD patients with simultaneous underlying at-risk comorbidities vs. matched controls without CDAD in the hospital setting, and from the payer perspective. This is the first study to our knowledge that examined outcomes and costs in multiple subpopulations at highest risk for CDAD and its recurrence. Although previous studies have assessed similar outcomes in specific risk groups, they were limited to evaluating only 1 risk group. By examining the characteristics of 6 high-risk groups, this study hopes to focus attention on the greater level of specific care and resources incurred by these patients. While this study introduces new data, it will be important to conduct additional studies with these and other at-risk patient populations associated with this increasingly problematic condition.
